Diarrhea News and Research

Latest Diarrhea News and Research

Vertex receives FDA approval for INCIVEK to treat hepatitis C

Vertex Pharmaceuticals Incorporated announced that the U.S. Food and Drug Administration (FDA) has approved INCIVEK™ (telaprevir) tablets for a broad group of people with genotype 1 chronic hepatitis C with compensated liver disease (some level of damage to the liver but the liver still functions), including cirrhosis (scarring of the liver).

23 May 2011

New RHUCIN study data in acute HAE attacks presented at 7th C1 Inhibitor Deficiency Workshop

Santarus, Inc., a specialty biopharmaceutical company, today announced that new data from open-label studies evaluating the efficacy and safety of the investigational drug RHUCIN for the treatment of acute attacks of angioedema in patients with Hereditary Angioedema were presented at the 7th C1 Inhibitor Deficiency Workshop on May 20 - 22, 2011 in Budapest, Hungary.

23 May 2011

FDA approves SUTENT for treatment of pancreatic NET

Pfizer Inc. announced today that the U.S. Food and Drug Administration (FDA) has approved SUTENT® (sunitinib malate) as the first anti-VEGF therapy to treat progressive, well-differentiated pancreatic neuroendocrine tumors (NET) in patients with unresectable locally advanced or metastatic disease. Pancreatic NET is a rare cancer reported in two to four people per million annually worldwide.

21 May 2011

Phase 3 open-label study of RELISTOR presented at American Pain Society meeting

Salix Pharmaceuticals, Ltd. today announced findings from two analyses of a Phase 3 open-label study of RELISTOR (methylnaltrexone bromide) presented at the 30th Annual Scientific Meeting of the American Pain Society. The meeting is being held in Austin, TX, on May 19-21, 2011.

21 May 2011

FDA approves Sutent for patients with progressive neuroendocrine cancerous tumors in pancreas

The U.S. Food and Drug Administration today approved Sutent (sunitinib) to treat patients with progressive neuroendocrine cancerous tumors located in the pancreas that cannot be removed by surgery or that have spread to other parts of the body (metastatic).

21 May 2011

Study examines long-term GI complications in childhood cancer survivors

Individuals who are treated for cancer during childhood have a significantly higher risk of developing gastrointestinal complications - from mild to severe - later in life, according to a study led by the University of California, San Francisco. The findings underscore the need for childhood cancer survivors and their physicians to be aware of these risk factors to ensure patients' ongoing health care needs are met.

21 May 2011

Merck's VICTRELIS receives European CHMP positive opinion for treatment of chronic HCV genotype 1 infection

Merck, today announced that the Committee for Medicinal Products for Human Use of the European Medicines Agency has adopted a positive opinion under accelerated assessment recommending approval of the investigational medicine VICTRELIS (boceprevir) for the treatment of chronic hepatitis C virus genotype 1 infection, in combination with peginterferon alfa and ribavirin, in adult patients with compensated liver disease who are previously untreated or who have failed previous therapy.

20 May 2011

Monitoring adherence to mandatory hand-washing protocols can help stop outbreaks of C. diff bacteria

Just like intelligence agents watching for the real terrorists threatening to attack, monitoring healthcare worker adherence to mandatory hand-washing protocols via hand-washing squads in hospitals can go a long way to stop outbreaks of the opportunistic C. diff bacteria, says Irena Kenneley, an infection prevention and control expert and assistant professor of nursing from the Frances Payne Bolton School of Nursing at Case Western Reserve University.

20 May 2011

Bayer, Onyx to present Nexavar-chemotherapy combination Phase 2b trial data in breast cancer at ASCO 2011

Bayer HealthCare Pharmaceuticals, Inc. and Onyx Pharmaceuticals, Inc. today announced results from a Phase 2b trial evaluating Nexavar® (sorafenib) tablets in patients with locally advanced or metastatic breast cancer previously treated with a bevacizumab-containing regimen, which showed that Nexavar was associated with statistically significant improvements in progression-free survival and time-to-progression.

20 May 2011

Naltrexone improves clinical, inflammatory activity in Crohn's disease patients

Naltrexone reduced inflammation in Crohn's patients in a research study at Penn State College of Medicine.

20 May 2011

$Positive results from Onyx's carfilzomib Phase 2b 003-A1 study in relapsed and refractory multiple myeloma$

Positive results from Onyx's carfilzomib Phase 2b 003-A1 study in relapsed and refractory multiple myeloma

Onyx Pharmaceuticals, Inc. today announced updated results from the Phase 2b 003-A1 study of single-agent carfilzomib, a next generation proteasome inhibitor, in patients with relapsed and refractory multiple myeloma. Carfilzomib achieved a clinical benefit rate (CBR) (minimal response or greater) in the study population of 37 percent with a duration of response (DOR) of 8.3 months.

20 May 2011

ViroPharma commences VP 20621 Phase 2 study for prevention of recurrent Clostridium difficile infection

ViroPharma Incorporated today announced initiation of a Phase 2 dose-ranging clinical study to evaluate the safety, tolerability, and efficacy of VP 20621 for prevention of recurrence of Clostridium difficile infection (CDI) in adults previously treated for CDI.

20 May 2011

USPTO grants four key patents for Alvine's proteases to detect celiac disease

Alvine Pharmaceuticals, Inc., a biopharmaceutical company focused on the treatment of autoimmune and gastrointestinal diseases, today announced that the United States Patent and Trademark Office has issued four key patents: 7,943,312; 7,928,056; 7,923,532; and 7,910,541, protecting various aspects of Alvine's core technology.

19 May 2011

Afghan Acting Health Minister says country wants to boost immunization access

Reuters featured an interview with Afghanistan's Acting Health Minister Suraya Dalil on the sidelines of the World Health Assembly in Geneva. "Afghanistan, whose government is fighting a worsening insurgency that has dragged on for nearly a decade since the U.S.-backed overthrow of the Taliban, is also plagued by poverty, malnutrition and corruption," Reuters writes, adding that the government and donors together spend "barely" $10 per person on health annually.

19 May 2011

Pfizer's axitinib Phase 3 trial in advanced renal cell carcinoma meets primary endpoints

Pfizer Inc. today announced data from the pivotal Phase 3 AXIS 1032 trial, showing that in patients with previously treated advanced renal cell carcinoma, axitinib significantly extended progression-free survival at the 47th Annual American Society of Clinical Oncology meeting in Chicago from June 3-7, 2011.

19 May 2011

New data on personalized approaches for skin, ovarian and lung cancer to be presented at ASCO meeting

Genentech, a member of the Roche Group, today announced that data showing new personalized approaches for people with skin and lung cancer, plus new data with Avastin in ovarian cancer, will be presented at the 47th Annual Meeting of the American Society of Clinical Oncology.

18 May 2011

Eli Lilly responds to Amylin's exenatide lawsuit

Eli Lilly and Company has provided additional perspective in response to Amylin Pharmaceuticals, Inc.'s lawsuit filed in the United States District Court for the Southern District of California.

17 May 2011

Amylin files lawsuit against Eli Lilly for improper commercialization of exenatide

Amylin Pharmaceuticals, Inc. today announced that it has filed a lawsuit against Eli Lilly and Company in the United States District Court for the Southern District of California, alleging that Lilly is engaging in anticompetitive activity and breaching its strategic alliance agreements with Amylin to maximize commercialization of exenatide.

16 May 2011

Two DIFICID Phase 3 trial data in C. difficile infection presented at AGS Annual Meeting

Optimer Pharmaceuticals today announced the presentation of an additional analysis of data from the company's two Phase 3 clinical trials of DIFICID, an investigational antibiotic for the treatment of Clostridium difficile Infection, at the American Geriatric Society (AGS) Annual Meeting held in National Harbor, Maryland.

13 May 2011

Irritable Bowel Syndrome linked to bacterial overgrowth, food poisoning

Cedars-Sinai researchers have reported two advances in the understanding of Irritable Bowel Syndrome, the most common gastrointestinal disorder in the United States, affecting an estimated 30 million people.

12 May 2011

Diarrhea News and Research

Latest Diarrhea News and Research

Vertex receives FDA approval for INCIVEK to treat hepatitis C

New RHUCIN study data in acute HAE attacks presented at 7th C1 Inhibitor Deficiency Workshop

FDA approves SUTENT for treatment of pancreatic NET

Phase 3 open-label study of RELISTOR presented at American Pain Society meeting

FDA approves Sutent for patients with progressive neuroendocrine cancerous tumors in pancreas

Study examines long-term GI complications in childhood cancer survivors

Merck's VICTRELIS receives European CHMP positive opinion for treatment of chronic HCV genotype 1 infection

Monitoring adherence to mandatory hand-washing protocols can help stop outbreaks of C. diff bacteria

Bayer, Onyx to present Nexavar-chemotherapy combination Phase 2b trial data in breast cancer at ASCO 2011

Naltrexone improves clinical, inflammatory activity in Crohn's disease patients

Positive results from Onyx's carfilzomib Phase 2b 003-A1 study in relapsed and refractory multiple myeloma

ViroPharma commences VP 20621 Phase 2 study for prevention of recurrent Clostridium difficile infection

USPTO grants four key patents for Alvine's proteases to detect celiac disease

Afghan Acting Health Minister says country wants to boost immunization access

Pfizer's axitinib Phase 3 trial in advanced renal cell carcinoma meets primary endpoints

New data on personalized approaches for skin, ovarian and lung cancer to be presented at ASCO meeting

Eli Lilly responds to Amylin's exenatide lawsuit

Amylin files lawsuit against Eli Lilly for improper commercialization of exenatide

Two DIFICID Phase 3 trial data in C. difficile infection presented at AGS Annual Meeting

Irritable Bowel Syndrome linked to bacterial overgrowth, food poisoning

Flow chemistry, AI, and NMR: A next-gen approach to scalable API production

Digital pathology and the PathoVerse: A conversation with Dr. Singh

Bioprocess Efficiency with Cell Density Monitoring

Diarrhea News and Research

Latest Diarrhea News and Research

Flow chemistry, AI, and NMR: A next-gen approach to scalable API production

Digital pathology and the PathoVerse: A conversation with Dr. Singh

Bioprocess Efficiency with Cell Density Monitoring

Newsletters you may be interested in